Novo Nordisk Abandons Ocedurenone After $816M Loss from Failed Phase 3 Trial in CKD

Nov 06, 2024 19:28 CST Updated 19:28

Novo Nordisk

Insulin Developer and Manufacturer

On November 6, Novo Nordisk abandoned a late-stage renal disease drug, which was acquired for $1.3 billion, after considering the impact of the Phase 3 clinical trial failure.Ocedurenone。

In October 2023, Novo Nordisk purchased a non-steroidal mineralocorticoid receptor antagonist from KBP Biosciences.Ocedurenone. The idea at the time was that the drug could be a competitor to Bayer's approved chronic kidney disease (CKD) drug, Kerendia. ($1.3 Billion! Novo Nordisk Introduces a Phase 3 Clinical New Drug Developed by a Chinese Biotech Company）

In July this year, when a pre-specified interim analysis of a Phase 3 trial for hypertension and advanced CKD showed that the trial failed to reach its primary endpoint of inducing a significant change in systolic blood pressure, those ambitious goals were dashed, leading toNovo NordiskHalted this research. This clinical failure brought Novo Nordisk an impairment loss of $816.5 million (The prediction may be the upfront payment for the acquisition.）。（Just Now! Novo Nordisk's Phase 3 Clinical Trial of KBP's New Drug Fails, Resulting in a Loss of $816 Million）

At that timeNovo NordiskIndicates that it is currently under evaluation.ocedurenoneWhether it has shown potential in other therapeutic areas.Novo NordiskHinted at plans to "launch more Phase 3 trials for cardiovascular and renal disease indications in the coming years."But after analyzing the "detailed experimental data",Novo NordiskNow it is decided to completely terminateocedurenone, which was confirmed in Novo Nordisk's latest Q3 financial report.

KBP BiosciencesLatest Management Team

With the disappearance of ocedurenone,Novo Nordisk PipelineThe only CKD project still listed in China is semaglutide, which succeeded in a phase 3 study this year for reducing the risk of kidney disease progression in patients with type 2 diabetes.

Follow the official account below to see the world!